Frauke Friedrichs

Frauke Friedrichs

Auto-generated profile, based on publicly available information

Frauke Friedrichs

Bayer, Pharmaceuticals, Clinical Statistics and Analytics, Wuppertal and Berlin, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2024 in Clinical and Translational Science
Verified
Journal Article
Open access
TLTianxing Liu
Tianxing Liu
KHKensei Hashizume
Kensei Hashizume
EKEva Krieg
Eva Krieg
HCHuijun Chen
Huijun Chen
YMYuki Mukaida
Yuki Mukaida
RYRosie Yu
Rosie Yu
The inhibition of coagulation factor XI (FXI) presents an attractive approach for anticoagulation as it is not expected to increase the risk of clinically relevant bleeding and is anticipated to be at least as effective as currently available anticoagulants. Fesomersen is a conjugated antisense oligonucleotide that selectively inhibits the expression of FXI. The article describes three clinical studies that investigated the safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of fesomersen after subcutaneous (s.c.) injection to healthy participants. The studies included participants from diverse ethnic backgrounds (Caucasian, Japanese, and Chinese). Fesomersen demonstrated good safety and tolerability in all three studies. No major bleeding events were observed. After single‐dose s.c. injection, fesomersen was rapidly absorbed into the systemic circulation, with maximum fesomersen‐equivalent (fesomersen‐eq) concentrations (Cmax) in plasma observed within a few hours. After reaching Cmax, plasma fesomersen‐eq concentrations declined in a biphasic fashion. The PD analyses showed that the injection of fesomersen led to dose‐dependent reductions in FXI activity and increases in activated partial thromboplastin time (aPTT). The maximum observed PD effects were reached between Day 15 and 30, and FXI activity and aPTT returned to near‐baseline levels by Day 90 after a single dose. The PK/PD profiles after a single injection were similar among the various ethnic groups. Collectively, the study results suggest that fesomersen has a favorable safety profile and predictable and similar PK and PD profiles across Chinese, Japanese, and Caucasian participants.

4 September 2025 in Dermatology and Therapy
Verified
Journal Article
Open access
PDF file
SJStefan J. Jodl
Stefan J. Jodl
MWMargitta Worm
Margitta Worm
FFFrauke Friedrichs
Frauke Friedrichs
UHUlrike Heinzel-Pleines
Ulrike Heinzel-Pleines
AWAndrea Wagenfeld
Andrea Wagenfeld
VPVidya Perera
Vidya Perera
Introduction Interleukin-1 receptor-associated kinase 4 (IRAK4) is expressed in various immune cells and regulates proinflammatory cytokine production. Its inhibition represents a novel, promising therapeutic option in the treatment of atopic dermatitis (AD). Zabedosertib (BAY1834845) is a potent, selective IRAK4 inhibitor that suppresses markers of local and systemic immune responses. This study aimed to evaluate the efficacy and safety of zabedosertib in adults with moderate-to-severe AD. Methods DAMASK was a randomized, double-blind, 12-week, placebo-controlled, phase 2a, proof-of-concept study. Patients were randomized 2:1 to receive oral zabedosertib 120 mg twice daily or placebo. The primary efficacy endpoint was a composite of 75% reduction from baseline on the Eczema Area and Severity Index (EASI-75), no discontinuation of study medication for lack of efficacy, no rescue medication during the 4 weeks before Day 84, and no initiation of systemic AD treatment. Other efficacy assessments included validated Investigator’s Global Assessment for Atopic Dermatitis (vIGA-AD), Peak Pruritus numerical rating scale score, and affected body surface area (BSA); for safety, it included frequency and severity of treatment-emergent adverse events (TEAEs). Results Of 77 randomized patients, 69 were included in the primary efficacy analysis (zabedosertib, n = 47; placebo, n = 22); 55 patients completed treatment. At Week 12, there was no significant difference between zabedosertib and placebo in the primary efficacy endpoint (32.3% vs. 37.4%) or percentage change in EASI from baseline (− 44.6% vs. − 55.9%). There were also no significant differences between zabedosertib and placebo at Week 12 in vIGA-AD response (15.9% vs. 28.5%), Peak Pruritus response (16.4% vs. 25.0%), percentage change in Peak Pruritus (− 20.7% vs. − 27.3%), or percentage change in BSA affected by AD (− 13.3% vs. − 20.3%). No severe or serious TEAEs were reported throughout the study. Conclusions Zabedosertib was safe and well tolerated in adults with moderate-to-severe AD but showed no evidence of efficacy in reducing disease severity or pruritus in this placebo-controlled study. Trial Registration ClinicalTrials.gov identifier, NCT05656911.